Search results for "PROGNOSIS"

showing 10 items of 2052 documents

A multicentre randomized controlled trial on trans-generational attention deficit/hyperactivity disorder (ADHD) in mothers and children (AIMAC): an e…

2018

Abstract. Objective: We examined predictors and moderators of treatment outcome in mothers and children diagnosed with ADHD in a large multicentre RCT. Method: In total, 144 mother-child dyads with ADHD were randomly assigned to either a maternal ADHD treatment (group psychotherapy and open methylphenidate medication, TG) or to a control treatment (individual counselling without psycho- or pharmacotherapy, CG). After maternal ADHD treatment, parent-child training (PCT) for all mother-child dyads was added. The final analysis set was based on 123 dyads with completed primary outcome assessments (TG: n = 67, CG: n = 56). The primary outcome was the change in each child’s externalizing sympto…

Treatment outcomeMotherslaw.inventionTrans generationalRandomized controlled trialChild of Impaired Parentslawmental disordersmedicineAttention deficit hyperactivity disorderHumans0501 psychology and cognitive sciencesChildbusiness.industry05 social sciencesGeneral MedicineExploratory analysismedicine.diseaseModerationPrognosis3. Good healthPsychiatry and Mental healthClinical PsychologyTreatment OutcomeAttention Deficit Disorder with HyperactivityPediatrics Perinatology and Child HealthMethylphenidatePsychotherapy GroupFemalebusiness050104 developmental & child psychologyClinical psychologyZeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie
researchProduct

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility

2017

The importance of the immune system as a potent anti-tumor defense has been consolidated in recent times, and novel immune-related therapies are today demonstrating a strong clinical benefit in the setting of several solid neoplasms. Tumor-infiltrating lymphocytes reflect the attempt of the host to eradicate malignancies, and during the last decades, they have been shown to possess an interesting prognostic utility for breast cancer, especially in case of HER2 positive and triple-negative molecular subtypes. In parallel, the clinical evaluation of tumor-infiltrating lymphocytes has been shown to effectively predict treatment outcomes in both neoadjuvant and adjuvant settings. Currently, tu…

Tumor-infiltrating lymphocytes; breast cancer; cancer immunotherapy0301 basic medicineOncologyCA15-3medicine.medical_specialtymedicine.medical_treatmentCA 15-3Tumor-infiltrating lymphocyteBreast NeoplasmsTumor-infiltrating lymphocytes03 medical and health sciencesLymphocytes Tumor-Infiltratingbreast cancer0302 clinical medicineImmune systemBreast cancerCancer immunotherapyInternal medicinemedicineHumansRC254-282cancer immunotherapyTumor-infiltrating lymphocytesbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerGeneral MedicinePrognosismedicine.diseaseNeoadjuvant TherapyTreatment Outcome030104 developmental biologyImmunoediting030220 oncology & carcinogenesisFemalebusinessTumor Biology
researchProduct

Clinical Recommendation Radical Trachelectomy for Fertility Preservation in Patients With Early-Stage Cervical Cancer

2012

Radical trachelectomy (RT) is a fertility-sparing procedure with the aim to provide adequate oncological safety to patients with cervical cancer while preserving their fertility. In the current review, indications, development of the procedure, technical aspects, preoperative and postoperative management, and oncological, fertility, and obstetric outcomes are discussed and studied with respect to whether the procedure is performed abdominally or vaginally. Complications of RT, staging, and more conservative alternatives to RT are discussed as well. A systematic MEDLINE search was performed, which yielded 218 articles, of which 75 were selected for further analysis based on the number of pat…

Uterine Cervical Neoplasmmedicine.medical_specialtyCervical cancer; Radical trachelectomy; Fertility preservationPrognosimedia_common.quotation_subjectmedicine.medical_treatmentUterine Cervical NeoplasmsTrachelectomyFertilityHysterectomyNeoadjuvant chemotherapyRadical trachelectomy03 medical and health sciences0302 clinical medicineAbdominal radical trachelectomymedicineHumansFertility preservationStage (cooking)CervixNeoadjuvant therapyOutcomeNeoplasm Stagingmedia_commonCervical cancerVaginal radical trachelectomy030219 obstetrics & reproductive medicineHysterectomybusiness.industryGeneral surgeryFertility PreservationObstetrics and GynecologyPrognosismedicine.diseaseNeoadjuvant Therapy3. Good healthSurgerymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCervical cancerLymph Node ExcisionFemalebusinessHumanInternational Journal of Gynecological Cancer
researchProduct

Vascular endothelial growth factor gene polymorphisms in ovarian cancer

2007

Abstract Background. Polymorphisms within the vascular endothelial growth factor (VEGF) gene, the most important regulator of angiogenesis and vascular permeability, were shown to be independently associated with an impaired prognosis in various malignancies. No data have been reported in ovarian cancer. Methods. In the present multi-center study, we examined three common polymorphisms within the VEGF gene ( VEGF +405G/C, VEGF −460C/T, and VEGF +936C/T) in 553 Caucasian patients with ovarian cancer using pyrosequencing. Results. The three investigated polymorphisms did not correlate with any of the investigated clinico-pathological parameters. In univariate and multivariate models, only FIG…

Vascular Endothelial Growth Factor AGenotypeAngiogenesisVEGF receptorsRegulatorVascular permeabilityLinkage Disequilibriumchemistry.chemical_compoundHumansMedicineGeneAgedNeoplasm StagingOvarian NeoplasmsPolymorphism GeneticNeovascularization Pathologicbiologybusiness.industryHaplotypeObstetrics and GynecologyMiddle AgedPrognosismedicine.diseaseVascular endothelial growth factorOncologychemistryCancer researchbiology.proteinFemalebusinessOvarian cancerGynecologic Oncology
researchProduct

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

2014

ACS : acute coronary syndrome AMPLIFY : Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy aPTT : activated partial thromboplastin time b.i.d. : bis in diem (twice daily) b.p.m. : beats per minute BNP : brain natriuretic peptide BP : blood pressure CI : confidence interval CO : cardiac output COPD : chronic obstructive pulmonary disease CPG : Committee for Practice Guidelines CRNM : clinically relevant non-major CT : computed tomographic/tomogram CTEPH : chronic thromboembolic pulmonary hypertension CUS : compression venous ultrasonography DSA : digital subtraction angiography DVT : deep vein thrombosis ELISA : enzyme-linked immunosorben…

Vitamin KVasodilator AgentsAdministration OralChest pain; Diagnosis; Dyspnoea; Guidelines; Heart failure; Hypotension; Pulmonary embolism; Shock; Thrombolysis; Treatment-Anticoagulation; Venousthrombosis; Administration Oral; Algorithms; Anticoagulants; Biomarkers; Chronic Disease; Clinical Laboratory Techniques; Diagnostic Imaging; Embolectomy; Endovascular Procedures; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Heart Failure; Home Care Services; Humans; Hypertension Pulmonary; Long-Term Care; Neoplasms; Pregnancy; Pregnancy Complications Cardiovascular; Prognosis; Pulmonary Embolism; Risk Factors; Vasoconstrictor Agents; Vasodilator Agents; Vitamin K; Cardiology and Cardiovascular MedicineEmbolectomyCardiovascularChest painPregnancyRisk FactorsNeoplasmsDiagnosisVasoconstrictor AgentsSocieties MedicalEndovascular ProceduresShockGeneral MedicinePulmonaryPrognosisThrombosisThrombolysisHome Care ServicesPulmonary embolismEuropeVenous thrombosismedicine.veinPractice Guidelines as TopicAdministrationHypertensionCardiologyApixabanFemaleRadiologyHypotensionCardiology and Cardiovascular MedicineAlgorithmsmedicine.drugOralDiagnostic Imagingmedicine.medical_specialtypumonary hypertensionmedicine.drug_classHypertension PulmonaryPregnancy Complications CardiovascularCardiologyMEDLINELow molecular weight heparin610 Medicine & healthHeart failureGuidelinesInferior vena cavaFibrin Fibrinogen Degradation ProductsText miningFibrinolytic AgentsInternal medicineDyspnoeamedicineHumansIntensive care medicinebusiness.industryClinical Laboratory TechniquesPulmonary embolismAnticoagulantsTreatment-Anticoagulationmedicine.diseasePulmonary hypertensionLong-Term CarePregnancy ComplicationsVenousthrombosisHeart failureChronic DiseasebusinessBiomarkers
researchProduct

Booster vaccination after neonatal priming with acellular pertussis vaccine.

2010

After a birth dose of acellular pertussis (aP) and diphtheria (DT)aP-hepatitis B virus (HBV)-inactivated polio vaccine (IPV)/ Haemophilus influenza type b (Hib) at 2, 4, and 6 months, a booster dose of DTaP-HBV-IPV/Hib at 12 to 23 months induced strong anti-pertussis booster responses. Thus, neonatal aP priming did not lead to immune tolerance to pertussis antigens. However, it elicited bystander interference on HBV, Hib, and diphtheria responses.

Whooping CoughFilamentous haemagglutinin adhesinImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesVirusPolio vaccineVaccines AcellularmedicineHumansWhooping coughHepatitis B virusPertussis VaccineDose-Response Relationship Drugbusiness.industryDiphtheriaVaccinationInfant Newbornvirus diseasesInfantmedicine.diseasePrognosisVirologyVaccinationPediatrics Perinatology and Child HealthImmunologybusinessFollow-Up StudiesThe Journal of pediatrics
researchProduct

Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic st…

2017

IF 7.702; International audience; The survival of patients with diffuse large B-cell lymphoma has increased during the last decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although the trend is encouraging, there are persistent differences in survival within and between the USA and European countries suggesting that non-biological factors play a role. Our aim was to investigate the influence of such factors on relative survival of patients with diffuse large B-cell lymphoma. We conducted a retrospective, multicenter, registry-based study in France on 1165 incident cases of diffuse large B-cell lymphoma between 2002 and 2008. Relative survival analyses were p…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyMale0301 basic medicinePediatricsMultivariate analysisMESH: RegistriesMESH : AgedMESH: ComorbidityComorbidityMESH : Lymphoma Large B-Cell DiffuseMESH: Aged 80 and over0302 clinical medicineInternational Prognostic IndexMESH : ChildMESH: ChildMESH : Population Surveillance[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleRegistriesYoung adultChildAged 80 and overMESH: AgedMESH: Middle AgedMESH : PrognosisRelative survivalMESH: Patient Outcome Assessment[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyArticlesHematologyMiddle AgedMESH : AdultPrognosisMESH : Patient Outcome Assessment3. Good healthMESH: Young AdultPopulation SurveillanceMESH: Survival Analysis030220 oncology & carcinogenesisMESH : ComorbidityMarital statusFemaleFranceLymphoma Large B-Cell DiffuseNon-Hodgkin LeukemiaAdultmedicine.medical_specialtyAdolescentMESH : MaleMESH: Factor Analysis StatisticalMESH : Young AdultMESH : Factor Analysis StatisticalMESH: PrognosisMESH: Population SurveillanceMESH: Social ClassYoung Adult03 medical and health sciencesMESH : AdolescentInternal medicineMESH : Social ClassmedicineHumansMESH : Middle AgedMESH : Aged 80 and overMESH : FranceSurvival analysisAgedMESH: AdolescentMESH: Humansbusiness.industryMESH : HumansMESH: Adultmedicine.diseaseSurvival AnalysisComorbidityMESH: MalePatient Outcome AssessmentMESH: France030104 developmental biologySocial ClassMESH: Lymphoma Large B-Cell DiffuseMESH : Survival AnalysisFactor Analysis StatisticalbusinessMESH: FemaleDiffuse large B-cell lymphomaMESH : RegistriesHaematologica
researchProduct

Cardiotoxicity of cancer therapy

2011

Despite the development of new anti-cancer drugs such as anti-tyrosine kinases or anti-angiogenic therapy, cancer mortality remains high. These new molecules associated with advances in cancer surgery, radiotherapy and chemotherapy have succeeded in improving life expectancy in these patients. It has also allowed a long-term evaluation of the cardiovascular impact of these therapies. Many chemotherapy drugs, such as anthracyclines, lead to impaired cardiac function. The pathophysiological mechanisms of this cardiac dysfunction are complex, intricate and remain partially unknown. To reduce this cardiotoxicity, different pathways concerning administration modalities, drug presentation and the…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyStress oxydantOxidative stress[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyAnthracyclinesPronostic cardiovasculaire[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCardiotoxicityCardiotoxicitéCardiovascular prognosisCancer
researchProduct

Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".

2018

Familial chylomicronaemia syndrome (FCS) is a rare, inherited disorder characterised by impaired clearance of triglyceride (TG)-rich lipoproteins from plasma, leading to severe hypertriglyceridaemia (HTG) and a markedly increased risk of acute pancreatitis. It is due to the lack of lipoprotein lipase (LPL) function, resulting from recessive loss of function mutations in the genes coding LPL or its modulators. A large overlap in the phenotype between FCS and multifactorial chylomicronaemia syndrome (MCS) contributes to the inconsistency in how patients are diagnosed and managed worldwide, whereas the incidence of acute hypertriglyceridaemic pancreatitis is more frequent in FCS. A panel of Eu…

[SDV]Life Sciences [q-bio]Diagnosis toolpopulation030204 cardiovascular system & hematologyburdenapoa50302 clinical medicineLoss of Function MutationRisk FactorsChylomicrons030212 general & internal medicineAge of OnsetHypolipidemic AgentsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Lipoprotein lipaseplasma triglycerideshyperlipoproteinemiaPrognosis3. Good healthUp-RegulationPhenotypeAcute pancreatitislipids (amino acids peptides and proteins)Hyperlipoproteinemia Type IAcute pancreatitis ; Familial chylomicronaemia syndrome ; Major hypertriglyceridaemia ; Multifactorial chylomicronaemiaCardiology and Cardiovascular MedicineFamilial chylomicronaemia syndromeAlgorithmsacute-pancreatitismedicine.medical_specialtyConsensushypertriglyceridemiaetiologyAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia/Decision Support TechniquesDiagnosis Differential03 medical and health sciencesAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia; Cardiology and Cardiovascular MedicinePredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseAcute pancreatitiBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.GenotypingTriglyceridesPregnancyReceiver operating characteristicbusiness.industrysevereMultifactorial chylomicronaemiaReproducibility of Resultsmutationslipoprotein-lipase genemedicine.diseaseConfidence intervalAcute pancreatitisLipoprotein LipasePancreatitisCardiovascular System & CardiologyPancreatitisMajor hypertriglyceridaemiabusinessBiomarkersAtherosclerosis
researchProduct

Type 2 Diabetes as a Factor Modifying the Course and Prognosis of Acute Pancreatitis

2022

Acute pancreatitis (AP) and type 2 diabetes (T2D) are diseases with steadily increasing incidence. On the one hand, the presence of diabetes increases the risk of AP development; on the other hand, there is a question whether the presence of T2D adversely affects the course and prognosis of AP. In this study we attempted to demonstrate the adverse effect of T2D on the course and prognosis of AP. Materials and methods:The retrospective study analyzed the data of 333 patients with the diagnosis of AP in the Internal Medicine Department of the University Hospital in Opole between 2015 and 2019. The patients were divided into two groups: with T2D and without T2D. The comparative analysis includ…

acute pancreatitisEndocrinology Diabetes and MetabolismInternal Medicinetype 2 diabetesprognosisClinical Diabetology
researchProduct